Advertisement

Topics

Bayer, Janssen’s Xarelto cuts risk of amputation, death

06:41 EST 13 Nov 2017 | PharmaTimes

Two new analyses of data from the COMPASS trial show that Bayer and Janssen’s blood thinner Xarelto significant cut the amputation rate for patients with peripheral artery disease and also a 23 percent reduction in deaths in patients with coronary artery disease.

Original Article: Bayer, Janssen’s Xarelto cuts risk of amputation, death

NEXT ARTICLE

More From BioPortfolio on "Bayer, Janssen’s Xarelto cuts risk of amputation, death"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...